Literature DB >> 10074505

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

T Rowe1, R A Abernathy, J Hu-Primmer, W W Thompson, X Lu, W Lim, K Fukuda, N J Cox, J M Katz.   

Abstract

From May to December 1997, 18 cases of mild to severe respiratory illness caused by avian influenza A (H5N1) viruses were identified in Hong Kong. The emergence of an avian virus in the human population prompted an epidemiological investigation to determine the extent of human-to-human transmission of the virus and risk factors associated with infection. The hemagglutination inhibition (HI) assay, the standard method for serologic detection of influenza virus infection in humans, has been shown to be less sensitive for the detection of antibodies induced by avian influenza viruses. Therefore, we developed a more sensitive microneutralization assay to detect antibodies to avian influenza in humans. Direct comparison of an HI assay and the microneutralization assay demonstrated that the latter was substantially more sensitive in detecting human antibodies to H5N1 virus in infected individuals. An H5-specific indirect enzyme-linked immunosorbent assay (ELISA) was also established to test children's sera. The sensitivity and specificity of the microneutralization assay were compared with those of an H5-specific indirect ELISA. When combined with a confirmatory H5-specific Western blot test, the specificities of both assays were improved. Maximum sensitivity (80%) and specificity (96%) for the detection of anti-H5 antibody in adults aged 18 to 59 years were achieved by using the microneutralization assay combined with Western blotting. Maximum sensitivity (100%) and specificity (100%) in detecting anti-H5 antibody in sera obtained from children less than 15 years of age were achieved by using ELISA combined with Western blotting. This new test algorithm is being used for the seroepidemiologic investigations of the avian H5N1 influenza outbreak.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074505      PMCID: PMC88628     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay.

Authors:  E J Remarque; I A de Bruijn; W J Boersma; N Masurel; G J Ligthart
Journal:  J Med Virol       Date:  1998-05       Impact factor: 2.327

2.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

3.  Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype.

Authors:  E A Govorkova
Journal:  Acta Virol       Date:  1997-10       Impact factor: 1.162

4.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus.

Authors:  E C Claas; A D Osterhaus; R van Beek; J C De Jong; G F Rimmelzwaan; D A Senne; S Krauss; K F Shortridge; R G Webster
Journal:  Lancet       Date:  1998-02-14       Impact factor: 79.321

5.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness.

Authors:  K Subbarao; A Klimov; J Katz; H Regnery; W Lim; H Hall; M Perdue; D Swayne; C Bender; J Huang; M Hemphill; T Rowe; M Shaw; X Xu; K Fukuda; N Cox
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

6.  Update: isolation of avian influenza A(H5N1) viruses from humans--Hong Kong, 1997-1998.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-01-09       Impact factor: 17.586

7.  A pandemic warning?

Authors:  J C de Jong; E C Claas; A D Osterhaus; R G Webster; W L Lim
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

8.  Pandemic influenza: a zoonosis?

Authors:  K F Shortridge
Journal:  Semin Respir Infect       Date:  1992-03

9.  Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.

Authors:  D C Powers; G E Smith; E L Anderson; D J Kennedy; C S Hackett; B E Wilkinson; F Volvovitz; R B Belshe; J J Treanor
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

10.  Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998.

Authors:  C Bender; H Hall; J Huang; A Klimov; N Cox; A Hay; V Gregory; K Cameron; W Lim; K Subbarao
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

View more
  352 in total

1.  Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus.

Authors:  Yuan Fang; Thomas Rowe; Alberto J Leon; David Banner; Ali Danesh; Luoling Xu; Longsi Ran; Steven E Bosinger; Yi Guan; Honglin Chen; Cheryl C Cameron; Mark J Cameron; David J Kelvin
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus.

Authors:  Jonathan A McCullers; Lee-Ann Van De Velde; Kim J Allison; Kristen C Branum; Richard J Webby; Patricia M Flynn
Journal:  Clin Infect Dis       Date:  2010-06-01       Impact factor: 9.079

3.  H5N1-SeroDetect EIA and rapid test: a novel differential diagnostic assay for serodiagnosis of H5N1 infections and surveillance.

Authors:  Surender Khurana; Pretty Sasono; Annette Fox; Van Kinh Nguyen; Quynh Mai Le; Quang Thai Pham; Tran Hien Nguyen; Thanh Liem Nguyen; Peter Horby; Hana Golding
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

4.  Establishment and characterization of a Madin-Darby canine kidney reporter cell line for influenza A virus assays.

Authors:  M Jaber Hossain; Sandra Perez; Zhu Guo; Li-Mei Chen; Ruben O Donis
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

5.  Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations.

Authors:  David K Hong; Adriana H Tremoulet; Jane C Burns; David B Lewis
Journal:  Pediatr Infect Dis J       Date:  2011-01       Impact factor: 2.129

6.  Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses.

Authors:  Adrian J Reber; Jin Hyang Kim; Renata Biber; H Keipp Talbot; Laura A Coleman; Tatiana Chirkova; F Liaini Gross; Evelene Steward-Clark; Weiping Cao; Stacie Jefferson; Vic Veguilla; Eric Gillis; Jennifer Meece; Yaohui Bai; Heather Tatum; Kathy Hancock; James Stevens; Sarah Spencer; Jufu Chen; Paul Gargiullo; Elise Braun; Marie R Griffin; Maria Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  Open Forum Infect Dis       Date:  2015-04-15       Impact factor: 3.835

7.  Two-dimensional antigenic dendrogram and phylogenetic tree of avian influenza virus H5N1.

Authors:  Alexander C K Lai; Wai-lan Wu; Siu-ying Lau; Yi Guan; Honglin Chen
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03

8.  H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.

Authors:  Irina Isakova-Sivak; Marina Stukova; Mariana Erofeeva; Anatoly Naykhin; Svetlana Donina; Galina Petukhova; Victoria Kuznetsova; Irina Kiseleva; Tatiana Smolonogina; Irina Dubrovina; Maria Pisareva; Alexandra Nikiforova; Maureen Power; Jorge Flores; Larisa Rudenko
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Authors:  Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

10.  A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development.

Authors:  Zoltan Vajo; John Wood; Lajos Kosa; Istvan Szilvasy; Gyorgy Paragh; Zsuzsanna Pauliny; Kálmán Bartha; Ildiko Visontay; Agnes Kis; Istvan Jankovics
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.